Please login to the form below

Not currently logged in
Email:
Password:

Astellas Europe appoints Ken Jones as CEO

Ken Jones, chief operating officer of Astellas Pharma Europe, has been appointed president and CEO of the company

Ken Jones has been appointed president and CEO of Astellas Pharma Europe – the European subsidiary of Japan-based Astellas Pharma.

Jones, who leaves his role of current chief operating officer with the company, takes over from Masao Yoshida who has been appointed as president and CEO of Astellas' US division.

"I am delighted and honoured to be taking on this new role and I look forward to building on Astellas Pharma Europe's considerable achievements," said Jones. "In spite of the tough market conditions which the industry is facing, we're in a strong position and have clear strategies for growth through expanding and developing our core franchises."

These strategies include expanding the company's efforts into pain management, anti-infectives and oncology while maintaining a leading presence in transplantation and urology.

In line with these plans, Astellas has entered several partnerships recently, including a deal with Optimer Pharmaceuticals involving the development and commercialisation in Europe of clostridium difficile treatment, fidaxomicin. Astellas has also agreed a partnership deal with AVEO Pharmaceuticals to develop investigational cancer treatment, tivozanib.

Jones joined Yamanouchi as vice president, European marketing, in 2003. Yamanouchi then merged with Fujisawa to form Astellas in 2005, with Jones being promoted to senior vice president, sales, marketing and medical.

Prior to his work with Astellas, he spent 16 years with Allergan working in Europe, the US and Japan.

11th April 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics